Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
- IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed -
“It is an exciting time for Solid as we work to advance our innovative pipeline designed to address Duchenne muscular dystrophy for all patients with this devastating disease,” said
- Announced in June that the
U.S. Food and Drug Administration( FDA) lifted the clinical hold on IGNITE DMD, Solid’s Phase I/II clinical trial for SGT-001 for the treatment of Duchenne muscular dystrophy (DMD). In connection with the lifting of the clinical hold, Solid made changes to the IGNITE DMD protocol, including adding an enhanced glucocorticoid regimen and additional monitoring measures, as well as a specification that eculizumab should be available as a treatment option if complement activation is observed in future patients. The Company plans to enroll and dose several children prior to dosing additional adolescents and now has the choice to obtain an intermediate muscle biopsy at 45 days post administration of SGT-001.
- Received approval from the
University of Florida Investigational Review Board(IRB) and resumed patient screening in IGNITE DMD at the University.
- Announced new preclinical data for SGT-001 at the 21st Annual Meeting of the
American Society of Gene and Cell Therapyin May, which further demonstrated its potential to be an important treatment approach for DMD. Specifically, long-term preclinical data demonstrated that a single intravenous administration of a low, medium or high dose of SGT-001 resulted in body-wide microdystrophin transgene expression that was sustained for at least 30 months, as well as restoration of key microdystrophin-associated proteins, including neuronal nitric oxide synthase (nNOS). In a different study, the restoration of nNOS and associated activity were shown to result in improvements in muscle histopathology and function in preclinical models, suggesting that nNOS activity could serve as an important marker of molecular function.
- Announced in June that the Company expanded its clinical development expertise with the appointment of biopharmaceutical veteran
Martin Freed, M.D., F.A.C.P., to its Board of Directors. Dr. Freed brings to Solid more than 25 years of strategic development and operational expertise from across the biopharmaceutical and life sciences industries. In addition, Ilan Ganotassumed the role of President after the retirement of Gilad Hayeemfrom his role as President and Director.
- Continued to progress its exploratory pipeline of next generation gene therapy assets, as well as its biomarker work intended to improve drug discovery and clinical development. This work includes an agreement with Flagship Biosciences to validate the use of its computational Tissue Analysis (cTA™) platform to quantify SGT-001-produced microdystrophin and additional signature proteins localized to the muscle membrane, such as nNOS, as supportive measures of microdystrophin function in IGNITE DMD.
- Continue to advance IGNITE DMD with the dosing of additional patients in the coming months and expanding the clinical trial footprint with additional sites both in the U.S. and abroad. The Company remains on track to communicate initial data from a pre-specified interim analysis in the second half of 2019.
Progressthe Company’s anti-LTBP4 monoclonal antibody program intended to reduce fibrosis and inflammation in the muscle. Solid continues development of its lead antibodies and remains on track to initiate preclinical activities by year end 2018.
Research and development expenses for the second quarter of 2018 were
General and administrative expenses were
Solid ended the second quarter of 2018 with
Solid’s lead candidate, SGT-001, is a novel adeno-associated viral (AAV) vector-mediated gene transfer under investigation for its ability to address the underlying genetic cause of Duchenne muscular dystrophy (DMD), mutations in the dystrophin gene that result in the absence or near-absence of dystrophin protein. SGT-001 is a systemically administered candidate that delivers a synthetic dystrophin transgene, called microdystrophin, to the body. This microdystrophin encodes for a functional protein surrogate that is expressed in muscles and stabilizes essential associated proteins, including neuronal nitric oxide synthase (nNOS). SGT-001 utilizes AAV9, which has an affinity for muscle and is currently being evaluated in multiple clinical programs in other indications. Data from Solid’s preclinical program suggest that SGT-001 has the potential to slow or stop the progression of DMD, regardless of genetic mutation or disease stage.
SGT-001 is based on pioneering research in dystrophin biology by Dr. Jeffrey Chamberlain of the University of Washington and Dr. Dongsheng Duan of the University of Missouri. SGT-001 has been granted Rare Pediatric Disease Designation, or RPDD, in the United States and Orphan Drug Designations in both the United States and European Union.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Solid’s IGNITE DMD clinical trial, its anticipated achievement of milestones and the potential of SGT-001. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, risks associated with Solid’s ability to obtain and maintain necessary approvals from the FDA and other regulatory authorities and investigational review boards at clinical trial sites; enroll patients in its clinical trials; continue to advance SGT-001 in clinical trials; replicate in later clinical trials positive results found in preclinical studies and earlier stages of clinical development; advance the development of its product candidates under the timelines it anticipates in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its product candidates; compete successfully with other companies that are seeking to develop DMD treatments and gene therapies; manage expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
|Solid Biosciences Inc.|
|Condensed Consolidated Statements of Operations|
|(unaudited, in thousands, except share and per share data)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Research and development||13,594||8,607||25,523||17,340|
|General and administrative||4,584||3,280||8,628||8,660|
|Total operating expenses||18,178||11,887||34,151||26,000|
|Loss from operations||(18,178||)||(11,887||)||(34,151||)||(26,000||)|
|Other income (expense):|
|Revaluation of preferred unit tranche rights||-||20||-||20|
|Total other income (expense), net||198||576||294||814|
|Net loss attributable to non-controlling interest||-||-||-||(1,060||)|
|Net loss attributable to Solid Biosciences Inc.||(17,980||)||(11,311||)||(33,857||)||(24,126||)|
|Accretion of preferred units to redemption value||-||-||-||(959||)|
|Redemption of preferred units||-||-||-||15,685|
|Redemption of redeemable interest from non-controlling interest in Solid GT||-||-||-||(1,925||)|
|Net loss attributable to common stockholders||$||(17,980||)||$||(11,311||)||$||(33,857||)||$||(11,325||)|
|Net loss per share attributable to common stockholders, basic and diluted||$||(0.52||)||$||(0.66||)||$||(1.06||)||$||(1.12||)|
|Weighted average shares of common stock outstanding, basic and diluted||34,449,758||17,041,311||31,916,295||10,083,502|
|Solid Biosciences Inc.|
|Condensed Consolidated Balance Sheets|
|(unaudited, in thousands, except share and per share data)|
|June 30,||December 31,|
|Cash and cash equivalents||$||145,824||$||52,080|
|Prepaid expenses and other current assets||1,714||1,499|
|Total current assets||164,473||70,658|
|Property and equipment, net||6,551||2,429|
|Other non-current assets||209||-|
|Deferred offering costs||-||3,106|
|Liabilities, Preferred Units and Stockholders' / Members' Equity / (Deficit)|
|Accrued expenses and other current liabilities||4,938||6,205|
|Total current liabilities||8,679||11,271|
|Other non-current liabilities||499||-|
|Series 2 Senior Preferred Units||-||55,002|
|Series 1 Senior Preferred Units||-||25,000|
|Junior Preferred Units||-||44,177|
|Stockholders' / Members' Equity / (Deficit)|
|Series A, B, C and D Common Units||-||65,014|
|Additional paid-in capital||320,382||-|
|Accumulated other comprehensive loss||(10||)||(13||)|
|Total stockholders' / members' equity (deficit)||162,292||(59,257||)|
|Total liabilities, preferred units and stockholders' / members' equity||$||171,470||$||76,193|
Kendall Investor Relations
Source: Solid Biosciences Inc.